Why Did Mesoblast (ASX:MSB) Shares Crash 7% Today?

Sonal Goyal

27 February 2026 05:45 PM AEDT

Why Did Mesoblast (ASX:MSB) Shares Crash 7% Today?

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

H1 total revenue surged to USD 51.3 million (AD 78.3 million) from USD 3.2 million, driven by the commercial launch of Ryoncil®.
Gross profit from Ryoncil® reached USD 44.2 million, with direct selling costs of USD 7.7 million.
Net loss narrowed to USD 40.2 million, down from USD 47.9 million in H1 FY2025, while period-end cash balance stood at USD 130 million.

Mesoblast Ltd (ASX:MSB) (Nasdaq:MESO) shares fell 7.02% to AUD 2.25 on 27 February 2026, following the release of its half-year financial results for the period ended 31 December 2025. The stock has declined 6.25% over the past five days and 8.54% over the past year.

Revenue Growth Driven by Ryoncil®

Mesoblast’s financial performance in H1 FY2026 was heavily influenced by the successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd). Gross sales of Ryoncil® reached USD 57.0 million, translating into USD 48.7 million revenue after gross-to-net adjustments. This resulted in a gross profit of USD 44.2 million, compared to nil in the previous corresponding period.

Total revenue for the half-year rose to USD 51.3 million (AD 78.3 million), reflecting the strong uptake of Ryoncil® at 49 transplant centers across the U.S., with coverage expected to extend to 64 centers performing 94% of relevant transplants.

Operational Highlights and Lifecycle Expansion

Mesoblast continues to expand Ryoncil® indications for both pediatric and adult patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The company is progressing Phase 3 trials for Ryoncil® lifecycle extension and its second-generation product, rexlemestrocel-L, targeting chronic low back pain (CLBP) and inflammatory chronic heart failure.

The Phase 3 CLBP trial is set to complete its 300-patient enrollment by March/April 2026 across 40 U.S. sites. Positive feedback from the FDA supports potential Biologics License Application (BLA) filings for these indications, leveraging single pivotal trial pathways.

Financial Position and Cash Flow

Despite reporting a net loss of USD 40.2 million, Mesoblast reduced its loss compared to H1 FY2025 (USD 47.9 million). Net operating cash outflows totaled USD 30.3 million. The period-end cash balance was USD 130 million, supplemented by a five-year USD 125 million non-dilutive credit facility, with USD 50 million available for drawdown until 30 June 2026.

The operating performance allows continued investment in R&D, commercial manufacturing of Ryoncil®, and clinical programs for rexlemestrocel-L.

Mesoblast’s H1 FY2026 results demonstrate significant revenue growth driven by the commercial launch of Ryoncil® and strategic development of its cellular therapy pipeline. The company maintains a robust cash position and access to additional financing to support lifecycle expansion and late-stage clinical programs.

FAQs

Q1: What was Mesoblast’s H1 FY2026 revenue?
Total revenue increased to USD 51.3 million (AD 78.3 million), up from USD 3.2 million in H1 FY2025.

Q2: How did the Ryoncil® launch perform?
Ryoncil® generated USD 57.0 million in gross sales, with a net revenue of USD 48.7 million and gross profit of USD 44.2 million.

Q3: What is the cash position of Mesoblast?
The company ended the period with USD 130 million in cash and a USD 125 million five-year credit facility, with USD 50 million available for drawdown.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.